Prednisone Indications and Dosing
Prednisone is indicated for a wide range of inflammatory and autoimmune conditions, with initial dosing typically ranging from 0.5-1 mg/kg/day (or 20-60 mg/day) depending on disease severity, followed by gradual tapering once clinical response is achieved. 1
Key Indications by Disease
Autoimmune Hepatitis (AIH)
- Initial dose: 0.5-1 mg/kg/day prednisolone, with higher doses (up to 1 mg/kg/day) reserved for severe/advanced disease 2
- Combination therapy: Should be combined with azathioprine (50 mg/day initially, increased to 1-2 mg/kg/day) when bilirubin <6 mg/dL, preferably starting azathioprine 2 weeks after corticosteroids 2
- Alternative: Mycophenolate mofetil (1.5-2 g/day) can substitute for azathioprine 2
- British guidelines recommend: Maximum 40 mg/day (or 0.5 mg/kg/day) to minimize adverse effects, with reduction below 20 mg as soon as possible 3
- Tapering: Reduce by 5-10 mg every 1-2 weeks over 3 months as transaminases fall, individualizing based on biochemical response 3
Sarcoidosis
- Initial dose: 20-40 mg/day per clinical guidelines 4
- Evidence shows: 40 mg/day (high-dose) offers no superiority over 20 mg/day (low-dose) for outcomes, relapse rates, or quality of life, but similar adverse effects 5
- Practical approach: Start with 20 mg/day for most patients; reserve higher doses for severe presentations
Giant Cell Arteritis (GCA)
- With acute visual/neurologic symptoms: IV methylprednisolone 250 mg every 6 hours for 3 days, then oral prednisone 80 mg/day (or 1 mg/kg) for 4-6 weeks 6
- Without acute symptoms: Start directly with oral prednisone 80 mg/day (or 1 mg/kg) 6
- Tapering: Reduce by 10 mg/day monthly; most require 1 year of therapy 6
Myasthenia Gravis
- Rapid-tapering regimen superior: Immediate high-dose 0.75 mg/kg/day, with earlier and rapid decrease once improved (39% success vs 9% with slow taper, sparing mean 1898 mg over 1 year) 7
- Always combine with azathioprine up to 3 mg/kg/day 7
Bullous Pemphigoid
- Mild to moderate disease: 0.5 mg/kg/day is effective (68.8% control at day 21 for moderate disease) 8
- Severe disease: Consider higher initial dosing (only 46.4% control at day 21 with 0.5 mg/kg/day) 8
General Dosing Principles
Administration Timing
- Give in the morning before 9 AM to minimize HPA axis suppression 1
- Take with food or milk to reduce gastric irritation 1
- Single daily dose preferred for most conditions 1
Initial Dosing Range
- 5-60 mg/day depending on disease severity 1
- Lower severity: lower doses suffice
- Higher severity: may require maximum doses
Tapering Strategy
- Never stop abruptly - always taper gradually 1
- Decrease in small increments at appropriate intervals to lowest effective maintenance dose 1
- Monitor constantly for disease activity changes 1
- After long-term therapy, adrenal insufficiency may persist up to 12 months post-discontinuation 1
Alternate-Day Therapy
- Consider for long-term treatment to minimize adverse effects (Cushingoid features, HPA suppression, growth suppression in children) 1
- Give twice the usual daily dose every other morning 1
Critical Monitoring and Prophylaxis
Bone Health
- Initiate prevention in all patients expected to receive ≥5 mg prednisone equivalent for ≥3 months 1
- Calcium and vitamin D supplementation 1, 6
- Bisphosphonates (alendronate, risedronate) if BMD below normal 1
- DEXA scanning at baseline and during follow-up 2
- Weight-bearing exercise 30-60 minutes daily 1
Ophthalmologic
- Baseline and periodic intraocular pressure monitoring (IOP elevated in two-thirds of children on long-term therapy) 2
- Monitor if therapy continues >6 weeks 1
Gastrointestinal
- PPI prophylaxis controversial: Consider only for high-dose (>30 mg/day) or prolonged therapy (>15 days) with additional risk factors, not routine 9
- Antacids between meals when large doses given 1
Common Pitfalls
- Inadequate initial dosing in severe disease leads to treatment failure
- Too-rapid tapering before achieving biochemical/clinical response causes relapse
- Failure to add steroid-sparing agent (azathioprine, mycophenolate) increases cumulative steroid exposure and adverse effects
- Neglecting bone protection in patients on chronic therapy
- Abrupt discontinuation risks adrenal crisis
- Missing drug interactions (macrolide antibiotics significantly decrease corticosteroid clearance) 1